[go: up one dir, main page]

PE20120571A1 - Produccion de titulos elevados de polivirus para la produccion de vacunas - Google Patents

Produccion de titulos elevados de polivirus para la produccion de vacunas

Info

Publication number
PE20120571A1
PE20120571A1 PE2012000051A PE2012000051A PE20120571A1 PE 20120571 A1 PE20120571 A1 PE 20120571A1 PE 2012000051 A PE2012000051 A PE 2012000051A PE 2012000051 A PE2012000051 A PE 2012000051A PE 20120571 A1 PE20120571 A1 PE 20120571A1
Authority
PE
Peru
Prior art keywords
poliovirus
production
cells
polivirus
titles
Prior art date
Application number
PE2012000051A
Other languages
English (en)
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PE20120571A1 publication Critical patent/PE20120571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN PROCESO PARA PRODUCIR UN POLIOVIRUS QUE COMPRENDE PROVEER UN CULTIVO DE CELULAS PER.C6 EN UNA SUSPENSION LIBRE DE SUERO, INFECTAR DICHAS CELULAS CON POLIOVIRUS EN UNA DENSIDAD CELULAR DE ENTRE 2X106 CELULAS/ML Y 150X106 CELULAS/ML Y COSECHAR LOS POLIOVIRUS ENTRE 12 Y 48 HORAS DESPUES DE LA INFECCION. EL POLIOVIRUS ES LA CEPA MAHONEY DEL POLIOVIRUS DEL TIPO 1, LA CEPA MEF DEL POLIOVIRUS DEL TIPO 2 O LA CEPA SAUKETT DEL POLIOVIRUS DEL TIPO 3. TAMBIEN ESTA REFERIDA A UNA VACUNA CONTRA LA POLIO QUE COMPRENDE A DICHO POLIOVIRUS, PURIFICADO Y OPCIONALMENTE, INACTIVADO
PE2012000051A 2009-07-16 2010-07-08 Produccion de titulos elevados de polivirus para la produccion de vacunas PE20120571A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16

Publications (1)

Publication Number Publication Date
PE20120571A1 true PE20120571A1 (es) 2012-06-06

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000051A PE20120571A1 (es) 2009-07-16 2010-07-08 Produccion de titulos elevados de polivirus para la produccion de vacunas

Country Status (32)

Country Link
US (4) US8546123B2 (es)
EP (1) EP2454364B1 (es)
JP (1) JP5845178B2 (es)
KR (1) KR101548790B1 (es)
CN (1) CN102482647B (es)
AP (1) AP3140A (es)
AR (1) AR077314A1 (es)
AU (1) AU2010272685B2 (es)
BR (1) BR112012000942B8 (es)
CA (1) CA2763091C (es)
CO (1) CO6491042A2 (es)
CU (1) CU20120006A7 (es)
DK (1) DK2454364T3 (es)
EA (1) EA020563B1 (es)
ES (1) ES2484093T3 (es)
HR (1) HRP20140597T1 (es)
IL (1) IL217465A (es)
MA (1) MA33429B1 (es)
MX (1) MX2011012648A (es)
MY (1) MY183385A (es)
NZ (1) NZ596880A (es)
PE (1) PE20120571A1 (es)
PL (1) PL2454364T3 (es)
PT (1) PT2454364E (es)
RS (1) RS53377B (es)
SG (1) SG177655A1 (es)
SI (1) SI2454364T1 (es)
SM (1) SMT201400079B (es)
TN (1) TN2011000628A1 (es)
TW (1) TWI477606B (es)
WO (1) WO2011006823A1 (es)
ZA (1) ZA201108271B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
MA33429B1 (fr) * 2009-07-16 2012-07-03 Crucell Holland Bv Production de poliovirus à titres élevés pour la production de vaccins
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
BR112015018493A2 (pt) * 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
KR102236498B1 (ko) 2013-03-08 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 무세포 백일해 백신
WO2014142433A1 (ko) 2013-03-13 2014-09-18 고려대학교산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
ES2689150T3 (es) 2013-06-17 2018-11-08 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Métodos para la prevención de agregación de componentes víricos
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
KR102423993B1 (ko) 2014-06-17 2022-07-22 얀센 백신스 앤드 프리벤션 비.브이. 저온-적응-바이러스-약독화(cava) 및 신규의 약독화 폴리오바이러스 균주
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
DK3172317T3 (da) 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
SG11202007503WA (en) 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP3969046A1 (en) 2019-05-16 2022-03-23 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
BRPI0409895B8 (pt) 2003-05-09 2021-05-25 Crucell Holland Bv método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células
CN104388324A (zh) 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
WO2007007344A1 (en) 2004-08-27 2007-01-18 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
NZ583291A (en) 2004-10-14 2011-06-30 Glaxosmithkline Biolog Sa Malaria prime/boost vaccines using adenoviral vectors and adjuvated proteins
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
MA33429B1 (fr) * 2009-07-16 2012-07-03 Crucell Holland Bv Production de poliovirus à titres élevés pour la production de vaccins
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
AU2010272685A1 (en) 2011-12-08
CU20120006A7 (es) 2012-10-15
SI2454364T1 (sl) 2014-08-29
US20140242670A1 (en) 2014-08-28
TW201118173A (en) 2011-06-01
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
CA2763091C (en) 2019-07-23
SMT201400079B (it) 2014-09-08
ZA201108271B (en) 2012-07-25
MA33429B1 (fr) 2012-07-03
US8546123B2 (en) 2013-10-01
CA2763091A1 (en) 2011-01-20
TWI477606B (zh) 2015-03-21
JP5845178B2 (ja) 2016-01-20
HRP20140597T1 (hr) 2014-09-12
US20110027317A1 (en) 2011-02-03
PT2454364E (pt) 2014-07-04
CN102482647B (zh) 2015-12-16
BR112012000942A2 (pt) 2016-03-15
DK2454364T3 (da) 2014-07-21
EA020563B1 (ru) 2014-12-30
KR101548790B1 (ko) 2015-08-31
RS53377B (sr) 2014-10-31
US20130052224A1 (en) 2013-02-28
IL217465A (en) 2016-05-31
AP3140A (en) 2015-02-28
US20130273106A1 (en) 2013-10-17
AP2012006075A0 (en) 2012-02-29
BR112012000942B1 (pt) 2020-10-27
US9022240B2 (en) 2015-05-05
JP2012532616A (ja) 2012-12-20
EP2454364A1 (en) 2012-05-23
PL2454364T3 (pl) 2014-09-30
SG177655A1 (en) 2012-02-28
ES2484093T3 (es) 2014-08-11
HK1164922A1 (en) 2012-09-28
TN2011000628A1 (en) 2013-05-24
IL217465A0 (en) 2012-02-29
EA201270173A1 (ru) 2012-06-29
BR112012000942B8 (pt) 2021-05-25
AR077314A1 (es) 2011-08-17
NZ596880A (en) 2013-10-25
CN102482647A (zh) 2012-05-30
KR20120033334A (ko) 2012-04-06
WO2011006823A1 (en) 2011-01-20
MX2011012648A (es) 2012-01-12
MY183385A (en) 2021-02-18
EP2454364B1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
PE20120571A1 (es) Produccion de titulos elevados de polivirus para la produccion de vacunas
MX362512B (es) Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MX350966B (es) Celulas madre pluripotentes.
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
CO6290704A2 (es) Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen.
SG178885A1 (en) Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
MX2010000944A (es) Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
AR062072A1 (es) Proceso mejorado para cultivar celulas
AR068485A1 (es) Plantas con rendimiento incrementado
WO2014123967A3 (en) Cell lines for virus production and methods of use
AR095354A1 (es) Métodos para el armado de bancos celulares de alta densidad
AR084715A1 (es) Fermentador para fermentar biomasa
AR097981A1 (es) Interferencia de la represión del factor de transcripción hd-zip de expresión génica para la producción de plantas con rasgos mejorados
TR201902192T4 (tr) Bir rüzgar türbini kanadı.
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.
EP2435558A4 (en) GENETICALLY CORRECTED NON-DISABLED INDUCED PLURIPOTENTER STEM CELLS
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων
JP2010166901A5 (es)
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
CL2008003820A1 (es) Metodo para producir el virus de estomatitis vesicular atenuado (vsv) en un cultivo celular que comprende introducir en un vector el gen vsv g optimizado; composicion inmunogenica que comprende el vsv atenuado; kit para producir el vsv.
AR092688A1 (es) Metodos y composiciones para aumentar la resistencia a nematodos en plantas
AR112851A1 (es) Procedimiento para la obtención de una glicoproteína con un mayor porcentaje de glicanos afucosilados
ES2479540T3 (es) Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades

Legal Events

Date Code Title Description
FG Grant, registration